Samarth Kulkarni Crispr Therapeutics Ag (CRSP) insider trading activity

Samarth Kulkarni is Chief Executive Officer of CRISPR Therapeutics AG. Currently has a direct ownership of 195,085 shares of CRSP, which is worth approximately $7.65 Million. The most recent transaction as insider was on Mar 21, 2025, when has been sold 10,031 shares (Common Shares) at a price of $41.23 per share, resulting in proceeds of $413,578. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 195K

0.11% 3M change

6.26% 12M change

Total Value Held $7.65 Million

Samarth Kulkarni Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 21 2025	SELL Open market or private sale	$413,578 $41.23 p/Share	10,031 Reduced 4.89%	195,085 Common Shares
Mar 20 2025	BUY Exercise of conversion of derivative security	-	19,688 Added 8.76%	205,116 Common Shares
Mar 12 2025	SELL Open market or private sale	$193,293 $43.32 p/Share	4,462 Reduced 2.35%	185,428 Common Shares
Mar 11 2025	SELL Open market or private sale	$423,054 $42.42 p/Share	9,973 Reduced 5.23%	180,890 Common Shares
Mar 11 2025	BUY Exercise of conversion of derivative security	-	9,000 Added 4.53%	189,890 Common Shares
Mar 10 2025	BUY Exercise of conversion of derivative security	-	19,250 Added 9.16%	190,863 Common Shares
Feb 19 2025	SELL Open market or private sale	$1,013,472 $55.2 p/Share	18,360 Reduced 9.66%	171,613 Common Shares
Feb 19 2025	SELL Open market or private sale	$365,798 $52.8 p/Share	6,928 Reduced 3.52%	189,973 Common Shares
Feb 18 2025	SELL Open market or private sale	$640,782 $55.05 p/Share	11,640 Reduced 5.58%	196,901 Common Shares
Feb 18 2025	BUY Exercise of conversion of derivative security	-	13,250 Added 5.97%	208,541 Common Shares
Dec 24 2024	BUY Exercise of conversion of derivative security	$222,903 $16.21 p/Share	13,751 Added 6.58%	195,291 Common Shares
Dec 02 2024	SELL Open market or private sale	$826,500 $55.1 p/Share	15,000 Reduced 7.63%	181,540 Common Shares
Nov 11 2024	SELL Open market or private sale	$1,675,500 $55.85 p/Share	30,000 Reduced 13.24%	196,540 Common Shares
Oct 14 2024	SELL Open market or private sale	$198,680 $46.28 p/Share	4,293 Reduced 1.86%	226,540 Common Shares
Oct 13 2024	BUY Exercise of conversion of derivative security	-	8,333 Added 3.48%	230,833 Common Shares
Aug 08 2024	SELL Bona fide gift	-	100,000 Reduced 31.01%	222,500 Common Shares
Apr 15 2024	SELL Open market or private sale	$1,177,661 $60.14 p/Share	19,582 Reduced 8.6%	208,122 Common Shares
Apr 15 2024	BUY Exercise of conversion of derivative security	$374,407 $19.12 p/Share	19,582 Added 7.92%	227,704 Common Shares
Mar 15 2024	SELL Open market or private sale	$1,450,200 $72.51 p/Share	20,000 Reduced 8.77%	208,122 Common Shares
Mar 15 2024	BUY Exercise of conversion of derivative security	$382,400 $19.12 p/Share	20,000 Added 8.06%	228,122 Common Shares
Mar 12 2024	SELL Open market or private sale	$341,158 $74.44 p/Share	4,583 Reduced 2.15%	208,122 Common Shares
Mar 11 2024	SELL Open market or private sale	$767,104 $78.26 p/Share	9,802 Reduced 4.59%	203,705 Common Shares
Mar 11 2024	BUY Exercise of conversion of derivative security	-	9,000 Added 4.06%	212,705 Common Shares
Mar 10 2024	BUY Exercise of conversion of derivative security	-	19,250 Added 8.27%	213,507 Common Shares
Feb 20 2024	SELL Open market or private sale	$507,497 $79.67 p/Share	6,370 Reduced 3.18%	194,257 Common Shares

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

RPTX

Repare Therapeutics Inc. Healthcare

CNTA

Centessa Pharmaceuticals plc Healthcare

Director